Credit score: Pixabay/CC0 Public Area
Allogeneic hematopoietic cell transplantation (allo-HCT) is possible in older sufferers with myelodysplastic syndrome (MDS), in accordance with a research revealed on-line June 26 within the European Journal of Haematology.
Fernando Barroso Duarte, Ph.D., from Walter Cantídio College Hospital in Fortaleza, Brazil, and colleagues performed a retrospective multicenter research to match outcomes and assess dangers related to allo-HCT in sufferers with MDS aged 65 years and older versus youthful than 65 years throughout 38 transplant facilities in Latin America from 1988 to 2023. A complete of 441 sufferers have been enrolled; 16% have been aged 65 years and older.
The researchers discovered that general survival (OS) was 49.3% and 56.7% in sufferers 65 years and older and people youthful than 65 years, respectively, at 5 years, and progression-free survival (PFS) was 48.4% and 56.2%, respectively. The cumulative incidence charges of relapse and nonrelapse mortality have been 13.6% and 33.8%, respectively. No important variations have been seen between the age teams in OS, nonrelapse mortality, or PFS after propensity rating matching. There was an affiliation seen between PFS in sufferers aged 65 years and older with high-risk Revised Worldwide Prognostic Scoring System stratification. A better danger for relapse was seen for sufferers aged 65 years and older in contrast with these aged youthful than 65 years. Prevalence danger was related to male intercourse, reduced-intensity conditioning, mobilized blood cells, and prior remedy in sufferers aged 65 years and older, whereas in these aged youthful than 65 years, associations have been seen with problems and persistent graft-versus-host illness.
“Allo-HCT is feasible in elderly patients with MDS, with no significant differences in OS or mortality risk compared to younger patients,” the authors write. “However, age may influence disease progression in very high-risk elderly patients with MDS, as well as the risk of relapse after transplantation. We identified that male sex, the use of a reduced-intensity conditioning regimen, and a mobilized blood cell graft are prevalent risk factors associated with elderly patients with MDS undergoing HCT.”
Extra info:
Fernando Barroso Duarte et al, Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older In comparison with Youngers. A Retrospective Evaluation of the Latin America Registry, European Journal of Haematology (2025). DOI: 10.1111/ejh.70001
Quotation:
Allogeneic HCT possible in older sufferers with myelodysplastic syndrome (2025, July 23)
retrieved 24 July 2025
from https://medicalxpress.com/information/2025-07-allogeneic-hct-feasible-older-patients.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
